World Journal of Hepatology
暂无分享,去创建一个
Sabyasachi Senapati | A. Pandey | Shashank Kumar | Ramesh Kumar | S. Singh | A. Singh | Shiv Amit Kumar Singh | Vardan Singh | Shiv Amit Kumar Singh
[1] A. Pandey,et al. Role of baicalin as a potential therapeutic agent in hepatobiliary and gastrointestinal disorders: A review , 2022, World journal of gastroenterology.
[2] Shenmin Zhang,et al. Letter: is it appropriate to use a fatty liver index >60 as an alternative criterion for non‐alcoholic fatty liver disease? , 2022, Alimentary pharmacology & therapeutics.
[3] Y. Jeng,et al. Tumor–matrix interaction induces phenotypic switching in liver cancer cells , 2022, Hepatology International.
[4] Reben Raeman,et al. Intestinal Barrier Dysfunction in Fatty Liver Disease: Roles of Microbiota, Mucosal Immune System, and Bile Acids. , 2022, Seminars in liver disease.
[5] M. Ryan,et al. The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma , 2022, Vaccines.
[6] I. Sheen,et al. Upper Gastrointestinal Cancer and Liver Cirrhosis , 2022, Cancers.
[7] A. Pandey,et al. Baicalin provides protection against fluoxetine-induced hepatotoxicity by modulation of oxidative stress and inflammation , 2022, World journal of hepatology.
[8] R. Gish,et al. Global incidence and mortality of hepatitis B and hepatitis C acute infections, cirrhosis and hepatocellular carcinoma from 2010 to 2019 , 2022, Journal of viral hepatitis.
[9] J. Marrero,et al. Risk factors for HCC in contemporary cohorts of patients with cirrhosis , 2022, Hepatology.
[10] B. Fromenty,et al. Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease , 2022, International journal of molecular sciences.
[11] P. Pajukanta,et al. β2-spectrin (SPTBN1) as a therapeutic target for diet-induced liver disease and preventing cancer development , 2021, Science Translational Medicine.
[12] Ren-jie Yang,et al. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. , 2021, Immunotherapy.
[13] O. Rehman,et al. Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma , 2021, Clinical and experimental hepatology.
[14] I. García-Alonso,et al. Curcumin Reduces Colorectal Cancer Cell Proliferation and Migration and Slows In Vivo Growth of Liver Metastases in Rats , 2021, Biomedicines.
[15] S. Mandlik,et al. An Overview of Hepatocellular Carcinoma with Emphasis on Dietary Products and Herbal Remedies , 2021, Nutrition and cancer.
[16] J. Llovet,et al. Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma , 2021, PLoS genetics.
[17] Xing-Xing He,et al. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets , 2021, Journal of Experimental & Clinical Cancer Research.
[18] R. Jia,et al. The role of SOCS proteins in the development of virus- induced hepatocellular carcinoma , 2021, Virology journal.
[19] T. Agarwal,et al. Critical signaling pathways governing hepatocellular carcinoma behavior; small molecule-based approaches , 2021, Cancer cell international.
[20] A. Singh,et al. Characterization of phytochemicals and validation of antioxidant and anticancer activity in some Indian polyherbal ayurvedic products , 2021, Vegetos.
[21] H. Koga,et al. Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis , 2021, Liver international : official journal of the International Association for the Study of the Liver.
[22] A. Singh,et al. Long non-coding RNA regulating androgen receptor signaling in breast and prostate cancer. , 2021, Cancer letters.
[23] E. Erdal,et al. Regulation of Wnt Signaling Pathways at the Plasma Membrane and Their Misregulation in Cancer , 2021, Frontiers in Cell and Developmental Biology.
[24] K. Schachtschneider,et al. Transcriptional regulation of alcohol induced liver fibrosis in a translational porcine hepatocellular carcinoma model. , 2021, Biochimie.
[25] I. Kurbatova,et al. [Hepatocellular damage and inflammation in various forms of alcoholic liver disease]. , 2021, Terapevticheskii arkhiv.
[26] Chen Wang,et al. βII spectrin (SPTBN1): biological function and clinical potential in cancer and other diseases , 2021, International journal of biological sciences.
[27] Amit Kumar Singh,et al. Antioxidant, anti-inflammatory and hepatoprotective activities of Terminalia bellirica and its bioactive component ellagic acid against diclofenac induced oxidative stress and hepatotoxicity , 2020, Toxicology reports.
[28] A. Bishayee,et al. Ferulic acid-mediated modulation of apoptotic signaling pathways in cancer. , 2021, Advances in protein chemistry and structural biology.
[29] Ashutosh Gupta,et al. Aceclofenac-induced hepatotoxicity: An ameliorative effect of Terminalia bellirica fruit and ellagic acid , 2020, World journal of hepatology.
[30] Chunye Zhang,et al. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer , 2020, Frontiers in Oncology.
[31] Xinyu Zhao,et al. Tumor-triggered personalized microRNA cocktail therapy for hepatocellular carcinoma. , 2020, Biomaterials science.
[32] I. Venditti,et al. Direct Conjugation of Resveratrol on Hydrophilic Gold Nanoparticles: Structural and Cytotoxic Studies for Biomedical Applications , 2020, Nanomaterials.
[33] N. Mahmud,et al. Acute on Chronic Liver Failure From Nonalcoholic Fatty Liver Disease: A Growing and Aging Cohort With Rising Mortality , 2020, Hepatology.
[34] Shinn-Ying Ho,et al. Novel miRNA signature for predicting the stage of hepatocellular carcinoma , 2020, Scientific Reports.
[35] Yushui Ma,et al. New Therapeutic Options for Advanced Hepatocellular Carcinoma , 2020, Cancer control : journal of the Moffitt Cancer Center.
[36] Xu‐yong Wei,et al. Is the era of sorafenib over? A review of the literature , 2020, Therapeutic advances in medical oncology.
[37] Amit Kumar Singh,et al. The Antioxidant and Antihyperglycemic Activities of Bottlebrush Plant (Callistemon lanceolatus) Stem Extracts , 2020, Medicines.
[38] P. Zhou,et al. A novel miR-0308-3p revealed by miRNA-seq of HBV-positive hepatocellular carcinoma suppresses cell proliferation and promotes G1/S arrest by targeting double CDK6/Cyclin D1 genes , 2020, Cell & Bioscience.
[39] A. Duseja,et al. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease. , 2019, Journal of clinical and experimental hepatology.
[40] I. Berindan‐Neagoe,et al. SIRT1 in the Development and Treatment of Hepatocellular Carcinoma , 2019, Front. Nutr..
[41] I. Sheen,et al. Sonic Hedgehog signaling pathway as a potential target to inhibit the progression of hepatocellular carcinoma , 2019, Oncology letters.
[42] Ashutosh Gupta,et al. Beneficial Effects of Dietary Polyphenols on Gut Microbiota and Strategies to Improve Delivery Efficiency , 2019, Nutrients.
[43] Hong Chang,et al. LINC01018 confers a novel tumor-suppressor role in hepatocellular carcinoma through sponging microRNA-182-5p. , 2019, American journal of physiology. Gastrointestinal and liver physiology.
[44] T. Manzia,et al. Liver transplantation for hepatocellular carcinoma: Where do we stand? , 2019, World journal of gastroenterology.
[45] Wei Cheng,et al. Deciphering the regulatory and catalytic mechanisms of an unusual SAM-dependent enzyme , 2019, Signal Transduction and Targeted Therapy.
[46] J. Copland,et al. Aberrant lipid metabolism as a therapeutic target in liver cancer , 2019, Expert opinion on therapeutic targets.
[47] A. Gemma,et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. , 2019, The Lancet. Oncology.
[48] M. Di Maio,et al. Second-line treatment options in hepatocellular carcinoma , 2019, Drugs in context.
[49] N. Sharma,et al. Synthesis and evaluation of the antiproliferative efficacy of BRM270 phytocomposite nanoparticles against human hepatoma cancer cell lines. , 2019, Materials science & engineering. C, Materials for biological applications.
[50] Guangdong Tong,et al. Compound Phyllanthus urinaria L Inhibits HBV-Related HCC through HBx-SHH Pathway Axis Inactivation , 2019, Evidence-based complementary and alternative medicine : eCAM.
[51] J. Danesh,et al. Mendelian Randomization Study of ACLY and Cardiovascular Disease , 2019, The New England journal of medicine.
[52] M. Kudo,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[53] H. Zuo,et al. Nano-Gold Loaded with Resveratrol Enhance the Anti-Hepatoma Effect of Resveratrol In Vitro and In Vivo. , 2019, Journal of biomedical nanotechnology.
[54] J. Marin,et al. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps , 2019, Archives of Toxicology.
[55] L. Kenner,et al. Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression. , 2019, Cytokine.
[56] Juan Wang,et al. Resveratrol represses estrogen‐induced mammary carcinogenesis through NRF2‐UGT1A8‐estrogen metabolic axis activation , 2018, Biochemical pharmacology.
[57] Wen-jie Li,et al. Liver-targeted delivery of liposome-encapsulated curcumol using galactosylated-stearate. , 2018, Experimental and therapeutic medicine.
[58] A. Pandey,et al. Hepatocellular Carcinoma: Causes, Mechanism of Progression and Biomarkers , 2018, Current chemical genomics and translational medicine.
[59] A. Bishayee,et al. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy , 2018, Nutrients.
[60] M. Kudo,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.
[61] Z. Zeng,et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities , 2018, Molecular Cancer.
[62] Y. Liu,et al. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[63] J. Bruix,et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. , 2017, Journal of hepatology.
[64] Yan Ding,et al. HGF/R-spondin1 rescues liver dysfunction through the induction of Lgr5+ liver stem cells , 2017, Nature Communications.
[65] R. Schwabe,et al. The gut microbiome and liver cancer: mechanisms and clinical translation , 2017, Nature Reviews Gastroenterology &Hepatology.
[66] J. Dufour,et al. Nonalcoholic fatty liver disease and hepatocellular carcinoma. , 2017, Hepatic oncology.
[67] P. Ulivi,et al. Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[68] T. Greten,et al. Liver cancer: Regorafenib as second-line therapy in hepatocellular carcinoma , 2017, Nature Reviews Gastroenterology &Hepatology.
[69] Mohammad A. Obeid,et al. Comparison of the physical characteristics of monodisperse non-ionic surfactant vesicles (NISV) prepared using different manufacturing methods. , 2017, International journal of pharmaceutics.
[70] F. Gao,et al. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway. , 2017, Oncology reports.
[71] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[72] A. Pandey,et al. Oxidative Stress-Related MicroRNAs as Diagnostic Markers: A Newer Insight in Diagnostics , 2017 .
[73] Jian-Li Hu,et al. Hepatitis B virus X protein and hypoxia‑inducible factor-1α stimulate Notch gene expression in liver cancer cells. , 2017, Oncology reports.
[74] Yuanyuan Ruan,et al. High expression of GFAT1 predicts poor prognosis in patients with pancreatic cancer , 2016, Scientific Reports.
[75] Jing Yuan,et al. Cirrhosis related functionality characteristic of the fecal microbiota as revealed by a metaproteomic approach , 2016, BMC Gastroenterology.
[76] M. Kudo,et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma , 2016, Journal of Gastroenterology.
[77] Yatang Chen,et al. Aberrant regulation of Wnt signaling in hepatocellular carcinoma , 2016, World journal of gastroenterology.
[78] Xiong Fu,et al. Preparation and Characterization of Microemulsions of Myricetin for Improving Its Antiproliferative and Antioxidative Activities and Oral Bioavailability. , 2016, Journal of agricultural and food chemistry.
[79] Ren Yan,et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. , 2016, Environmental microbiology.
[80] Yuchao Chen,et al. Pharmacokinetics and tissue distribution of docetaxel liposome mediated by a novel galactosylated cholesterol derivatives synthesized by lipase-catalyzed esterification in non-aqueous phase , 2016, Drug delivery.
[81] Y. Saga,et al. The hepatocyte growth factor antagonist NK4 inhibits indoleamine-2,3-dioxygenase expression via the c-Met-phosphatidylinositol 3-kinase-AKT signaling pathway , 2016, International journal of oncology.
[82] Xiangdong Gao,et al. A novel anti-alpha-fetoprotein single-chain variable fragment displays anti-tumor effects in HepG2 cells as a single agent or in combination with paclitaxel , 2016, Tumor Biology.
[83] H. Rupasinghe,et al. Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. , 2015, Chemico-biological interactions.
[84] I. Pastan,et al. New Life for Immunotoxin Cancer Therapy , 2015, Clinical Cancer Research.
[85] L. Roberts,et al. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma , 2015, Scientific Reports.
[86] Ying Cheng,et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2015, The Lancet. Oncology.
[87] Tian-ming Yang,et al. Chemical composition of total flavonoids from Polygonum amplexicaule and their pro-apoptotic effect on hepatocellular carcinoma cells: Potential roles of suppressing STAT3 signaling. , 2015, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[88] S. Prasad,et al. Ginger and Its Constituents: Role in Prevention and Treatment of Gastrointestinal Cancer , 2015, Gastroenterology research and practice.
[89] Mitchell Ho,et al. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signaling and protein synthesis , 2015, Nature Communications.
[90] Der-Zen Liu,et al. Galactosylated liposome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity. , 2015, Acta biomaterialia.
[91] D. Sindram,et al. The effect of alcohol on Sirt1 expression and function in animal and human models of hepatocellular carcinoma (HCC). , 2015, Advances in experimental medicine and biology.
[92] J. Zucman‐Rossi,et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis , 2014, Hepatology.
[93] Reka Albert,et al. Network modeling of TGFβ signaling in hepatocellular carcinoma epithelial-to-mesenchymal transition reveals joint sonic hedgehog and Wnt pathway activation. , 2014, Cancer research.
[94] A. Saxena,et al. Cell cycle inhibitory activity of Piper longum against A549 cell line and its protective effect against metal-induced toxicity in rats. , 2014, Indian journal of biochemistry & biophysics.
[95] Min Huang,et al. SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo. , 2014, Cancer letters.
[96] N. Desai,et al. Characterization of phytochemicals and evaluation of anti-cancer potential of Blumea eriantha DC. , 2014, Physiology and Molecular Biology of Plants.
[97] Sei-Jung Lee,et al. ZPDC glycoprotein (24 kDa) induces apoptosis and enhances activity of NK cells in N-nitrosodiethylamine-injected Balb/c. , 2014, Cellular immunology.
[98] Jessica Zucman-Rossi,et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. , 2014, Cancer cell.
[99] S. Thorgeirsson,et al. Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. , 2014, Journal of hepatology.
[100] A. Pandey,et al. Chemistry and Biological Activities of Flavonoids: An Overview , 2013, TheScientificWorldJournal.
[101] B. Guiu,et al. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. , 2013, Critical reviews in oncology/hematology.
[102] T. Yau,et al. The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance , 2013, PloS one.
[103] M. Salvador,et al. Suppression of oncoprotein Her-2 and DNA damage after treatment with Flavan-3- ol vitis labrusca extract. , 2013, Anti-cancer agents in medicinal chemistry.
[104] Prachi Gupta,et al. Evaluating the effect of lycopene from Lycopersicum esculentum on apoptosis during NDEA induced hepatocarcinogenesis. , 2013, Biochemical and biophysical research communications.
[105] Chih-Chieh Hsu,et al. Optimizing manufacture of liposomal berberine with evaluation of its antihepatoma effects in a murine xenograft model. , 2013, International journal of pharmaceutics.
[106] F. Abas,et al. Novel molecular, cytotoxical, and immunological study on promising and selective anticancer activity of Mung bean sprouts , 2012, BMC Complementary and Alternative Medicine.
[107] C. Croce,et al. Liver tumorigenicity promoted by microRNA‐221 in a mouse transgenic model , 2012, Hepatology.
[108] Vladimir Torchilin,et al. Best Practices in Cancer Nanotechnology: Perspective from NCI Nanotechnology Alliance , 2012, Clinical Cancer Research.
[109] A. Tsatsakis,et al. Chemoprevention of liver cancer by plant polyphenols. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[110] Raul Rabadan,et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. , 2012, Cancer cell.
[111] S. Fan,et al. A Garlic Derivative, S-allylcysteine (SAC), Suppresses Proliferation and Metastasis of Hepatocellular Carcinoma , 2012, PloS one.
[112] M. Sivalingam,et al. Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. , 2011, Molecular medicine reports.
[113] L. Hennighausen,et al. Growth hormone–STAT5 regulation of growth, hepatocellular carcinoma, and liver metabolism , 2011, Annals of the New York Academy of Sciences.
[114] E. Nevo,et al. Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. , 2011, Carcinogenesis.
[115] Kuen-Feng Chen,et al. Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells , 2011, Journal of Pharmacology and Experimental Therapeutics.
[116] G. Yen,et al. Anti-invasion effects of 6-shogaol and 6-gingerol, two active components in ginger, on human hepatocarcinoma cells. , 2010, Molecular nutrition & food research.
[117] S. Culine,et al. Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice , 2010, Molecular Cancer Therapeutics.
[118] J. Y. Kim,et al. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1- and NF-kappaB-dependent pathways. , 2010, Journal of molecular biology.
[119] J. Corton,et al. Transcriptional changes associated with reduced spontaneous liver tumor incidence in mice chronically exposed to high dose arsenic. , 2009, Toxicology.
[120] In‐Seon Lee,et al. Induction of apoptosis by immature plum in human hepatocellular carcinoma. , 2009, Journal of medicinal food.
[121] M. Friedman,et al. Tomatine-containing green tomato extracts inhibit growth of human breast, colon, liver, and stomach cancer cells. , 2009, Journal of agricultural and food chemistry.
[122] L. Bolondi,et al. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism. , 2009, Journal of hepatology.
[123] P. Galle,et al. Safety and Efficacy of Sorafenib in Patients With Advanced Hepatocellular Carcinoma in Consideration of Concomitant Stage of Liver Cirrhosis , 2009, Journal of clinical gastroenterology.
[124] W. Liu,et al. Asparanin A induces G(2)/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. , 2009, Biochemical and biophysical research communications.
[125] Anwar Anwar-mohamed,et al. Sulforaphane induces CYP1A1 mRNA, protein, and catalytic activity levels via an AhR-dependent pathway in murine hepatoma Hepa 1c1c7 and human HepG2 cells. , 2009, Cancer letters.
[126] C. Borek,et al. Lycium barbarum (goji) juice improves in vivo antioxidant biomarkers in serum of healthy adults. , 2009, Nutrition research.
[127] In‐Seon Lee,et al. Inhibitory effects of methanol extract of plum (Prunus salicina L., cv. 'Soldam') fruits against benzo(alpha)pyrene-induced toxicity in mice. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[128] M. Bardella,et al. Resveratrol inhibits cell growth in a human cholangiocarcinoma cell line , 2008, Liver international : official journal of the International Association for the Study of the Liver.
[129] A. Paradiso,et al. Molecular pathways and related target therapies in liver carcinoma. , 2007, Current pharmaceutical design.
[130] L. Bolondi,et al. Aberrant Notch3 and Notch4 expression in human hepatocellular carcinoma , 2007, Liver international : official journal of the International Association for the Study of the Liver.
[131] Ching-Hsein Chen,et al. Isoobtusilactone A-induced apoptosis in human hepatoma Hep G2 cells is mediated via increased NADPH oxidase-derived reactive oxygen species (ROS) production and the mitochondria-associated apoptotic mechanisms. , 2007, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[132] Kook Hwan Kim,et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. , 2007, Gastroenterology.
[133] Kook Hwan Kim,et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. , 2007, Gastroenterology.
[134] S. Wilhelm,et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.
[135] M. Kampa,et al. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. , 2006, Biochimica et biophysica acta.
[136] M. Lila,et al. Cytotoxicity of bioactive polymeric fractions from grape cell culture on human hepatocellular carcinoma, murine leukemia and non-cancerous PK15 kidney cells. , 2006, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[137] Takuji Tanaka,et al. Suppression of beta-catenin mutation by dietary exposure of auraptene, a citrus antioxidant, in N,N-diethylnitrosamine-induced hepatocellular carcinomas in rats. , 2005, Oncology reports.
[138] Hong-shan Liu,et al. Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. , 2003, World journal of gastroenterology.
[139] M. Gariboldi,et al. Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. , 2002, Carcinogenesis.
[140] N. Latruffe,et al. Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. , 2000, Oncology reports.